

## CONTENTS

NOTE TO THE READER .....	1
LIST OF PARTICIPANTS .....	3
PREAMBLE .....	7
A. GENERAL PRINCIPLES AND PROCEDURES .....	9
1. Background .....	9
2. Objective and scope .....	10
3. Selection of agents for review .....	12
4. Data for the <i>Monographs</i> .....	12
5. Meeting participants.....	13
6. Working procedures.....	14
B. SCIENTIFIC REVIEW AND EVALUATION .....	15
1. Exposure data .....	16
2. Studies of cancer in humans .....	18
3. Studies of cancer in experimental animals .....	23
4. Mechanistic and other relevant data.....	26
5. Summary .....	30
6. Evaluation and rationale.....	31
References.....	36
GENERAL REMARKS .....	39
THE MONOGRAPHS .....	41
<b>Ingested nitrate and nitrite</b> .....	43
1. Exposure Data .....	45
1.1 Chemical and physical data .....	46
1.2 Analysis.....	50
1.3 Production and use of major nitrate and nitrite salts .....	50
1.4 Occurrence .....	67
1.5 Exposure.....	89

1.6	Regulations and guidelines.....	97
1.7	References .....	100
2.	Studies of Cancer in Humans .....	111
2.1	Introduction .....	111
2.2	Stomach and oesophageal cancer .....	113
2.3	Tumours of the brain.....	152
2.4	Cancer of the urinary tract.....	177
2.5	Genital and breast cancer.....	193
2.6	Leukaemia and lymphoma .....	195
2.7	Oral, pharyngeal and laryngeal cancers.....	204
2.8	Nasopharyngeal cancer .....	214
2.9	Colon and rectal cancers.....	215
2.10	Pancreatic cancer .....	220
2.11	Lung.....	225
2.12	Liver.....	226
2.13	References .....	226
3.	Studies of Cancer in Experimental Animals .....	235
3.1	Nitrate.....	235
3.2	Nitrite .....	236
3.3	References .....	260
4.	Mechanistic and Other Relevant Data .....	266
4.1	Absorption, distribution, metabolism, and excretion .....	266
4.2	Genetic and related effects .....	278
4.3	Nitrosamines and cancer .....	285
4.4	Other relevant toxic effects.....	289
4.5	Mechanistic considerations .....	294
4.6	References .....	297
5.	Summary of Data Reported .....	313
5.1	Exposure data .....	313
5.2	Human carcinogenicity data .....	314
5.3	Animal carcinogenicity data.....	320
5.4	Other relevant data .....	322
6.	Evaluation and Rationale.....	325
	<b>Cyanobacterial peptide toxins .....</b>	<b>327</b>
1.	Exposure data .....	329
1.1	Introduction .....	329
1.2	Chemical and physical properties .....	330
1.3	Analysis.....	334
1.4	Occurrence .....	335
1.5	Human exposure.....	340
1.6	Regulations, guidelines and preventive measures.....	348

1.7	References .....	354
2.	Studies of Cancer in Humans .....	360
2.1	Hepatocellular carcinoma .....	360
2.2	Colorectal cancer .....	362
2.3	References .....	363
3.	Studies of Cancer in Experimental Animals .....	364
3.1	Pure microcystin-LR .....	364
3.2	Microcystis extracts .....	367
3.3	Nodularin .....	368
3.4	References .....	369
4.	Mechanistic and Other Relevant Data .....	370
4.1	Absorption, distribution, metabolism and excretion .....	370
4.2	Genetic and related effects .....	388
4.3	Mechanisms associated with the tumour promotion of microcystin-LR and nodularin .....	390
4.4	Other relevant toxic effects .....	394
4.5	References .....	398
5.	Summary of Data Reported .....	408
5.1	Exposure data .....	408
5.2	Human carcinogenicity data .....	409
5.3	Animal carcinogenicity data .....	409
5.4	Other relevant data .....	410
6.	Evaluation and Rationale .....	412
	LIST OF ABBREVIATIONS .....	413
	CUMULATIVE INDEX TO THE <i>MONOGRAPHS</i> SERIES .....	417

## NOTE TO THE READER

The term ‘carcinogenic risk’ in the *IARC Monographs* series is taken to mean that an agent is capable of causing cancer under some circumstances. The *Monographs* evaluate cancer hazards, despite the historical presence of the word ‘risks’ in the title.

Inclusion of an agent in the *Monographs* does not imply that it is a carcinogen, only that the published data have been examined. Equally, the fact that an agent has not yet been evaluated in a *Monograph* does not mean that it is not carcinogenic.

The evaluations of carcinogenic risk are made by international working groups of independent scientists and are qualitative in nature. No recommendation is given for regulation or legislation.

Anyone who is aware of published data that may alter the evaluation of the carcinogenic risk of an agent to humans is encouraged to make this information available to the Section of IARC Monographs, International Agency for Research on Cancer, 150 cours Albert Thomas, 69372 Lyon Cedex 08, France, in order that the agent may be considered for re-evaluation by a future Working Group.

Although every effort is made to prepare the monographs as accurately as possible, mistakes may occur. Readers are requested to communicate any errors to the Section of IARC Monographs, so that corrections can be reported in future volumes.